Market capitalization | CHF42.95m |
Enterprise Value | CHF43.43m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.87 |
P/S ratio (TTM) P/S ratio | 0.87 |
P/B ratio (TTM) P/B ratio | 0.71 |
Revenue growth (TTM) Revenue growth | -7.34% |
Revenue (TTM) Revenue | CHF49.65m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast SHL Telemedicine:
1 Analyst has issued a forecast SHL Telemedicine:
Jun '24 |
+/-
%
|
||
Revenue | 50 50 |
7%
7%
|
|
Gross Profit | 23 23 |
4%
4%
|
|
EBITDA | 1.33 1.33 |
383%
383%
|
EBIT (Operating Income) EBIT | -5.68 -5.68 |
22%
22%
|
Net Profit | -7.84 -7.84 |
270%
270%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SHL Telemedicine Ltd. engages in the development and market of advanced personal telemedicine solutions, which focuses on cardiovascular and related diseases. Its products and solutions include congestive heart failure, chronic obstructive pulmonary disease and cardiac monitoring services. The company was founded by Yoram Alroy and Elon Shalev in 1987 and is headquartered in Tel Aviv, Israel.
Head office | Israel |
CEO | David Arnon |
Employees | 583 |
Founded | 1987 |
Website | www.shl-telemedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.